

DEMONSTRATED IMPROVEMENT IN OVERALL FUNCTION (SDS score)

from baseline at 8 weeks with Trintellix 20 mg vs placebo (secondary endpoint):



Up to **87%** improvement in **OVERALL FUNCTION** (-8.4 vs -4.5; $p=0.0005$)^{1*†}



Up to **86%** improvement in function at **WORK** (-2.6 vs -1.4; $p=0.0059$)^{1*†}



Up to **82%** improvement in function at **HOME** (-3.1 vs -1.7; $p<0.0001$)^{1*†}



Up to **82%** improvement in function in a **SOCIAL SETTING** (-3.1 vs -1.7; $p<0.0001$)^{1*†}

† The starting and recommended dose of Trintellix is 10 mg once daily for adults <65 years of age. See the Product Monograph for complete dosing and administration information.

Clinical use:

Efficacy in providing symptomatic relief of MDD demonstrated in trials of up to 8 weeks' duration; efficacy in maintaining an antidepressant response demonstrated for up to 24 weeks.

Physicians who elect to use Trintellix for extended periods should periodically re-evaluate the usefulness of the drug for individual patients.

The lowest effective dose of 5 mg/day should always be used as the starting dose in elderly patients (≥65 years of age).

Not indicated in patients <18 years of age.

Contraindication:

- Combined use with monoamine oxidase inhibitors (MAOIs)

Most serious warnings and precautions:

- **Potential association with behavioural and emotional changes, including self-harm:** Severe agitation-type events reported; rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages; this includes monitoring for agitation-type emotional and behavioural changes.
- **Discontinuation symptoms:** Gradual reduction in dose, rather than abrupt cessation, is recommended.

Other relevant warnings and precautions:

- Dependence/tolerance
- Caution when driving or operating machinery
- Abnormal bleeding
- Potential for increased risk of postpartum hemorrhage
- Caution in moderate or severe hepatic impairment
- Bone fracture risk
- Caution in patients who have a history of seizures or in patients with unstable epilepsy
- Serotonin syndrome/neuroleptic malignant syndrome
- Cognitive and motor disturbances
- Angle-closure glaucoma
- Caution in patients with a history of mania/hypomania and discontinue use in any patient entering a manic phase
- Aggression/agitation
- Caution with concurrent use of electroconvulsive therapy (ECT)
- Hyponatremia

- Caution in patients with severe renal insufficiency
- Not recommended during breastfeeding
- Dosage adjustment in elderly patients

For more information:

Consult the Product Monograph at www.trintellixmonograph.ca for important information about contraindications, warnings, precautions, adverse reactions, interactions, dosing instructions and conditions of clinical use not discussed in this piece.

The Product Monograph is also available by calling 1-800-586-2325.

DSM=Diagnostic and Statistical Manual of Mental Disorders; DSST=Digit Symbol Substitution Test; HAM-A=Hamilton Anxiety Rating Scale; MADRS=Montgomery-Åsberg Depression Rating Scale; MDD=major depressive disorder; MDE=major depressive episode; SDS=Sheehan Disability Scale

* Double-blind, fixed-dose, placebo-controlled study of 608 patients aged 18-75 years with a primary diagnosis of recurrent MDD according to DSM-IV-TR criteria, a current MDE >3 months' duration and a MADRS total score ≥26. Patients were randomized to Trintellix 15 mg, 20 mg (10 mg/day during Weeks 1 and 15 or 20 mg/day from Weeks 2 to 8) or placebo for 8 weeks. Mean baseline MADRS total scores were 31.5 for placebo, 31.8 for Trintellix 15 mg and 31.2 for Trintellix 20 mg. Mean baseline SDS total scores were 19.8 for placebo, 20.6 for Trintellix 15 mg and 20.7 for Trintellix 20 mg. Mean baseline SDS work scores were 6.3 for placebo, 6.8 for Trintellix 15 mg and 6.9 for Trintellix 20 mg. Mean baseline SDS social scores were 6.8 for placebo, 6.9 for Trintellix 15 mg and 6.8 for Trintellix 20 mg. Mean baseline SDS family scores were 6.9 for placebo, 6.7 for Trintellix 15 mg and 7.0 for Trintellix 20 mg.^{1,2}

† Double-blind, fixed-dose, placebo-controlled, active reference study of 429 patients aged 18-65 with MDD presenting with a current MDE according to DSM-IV-TR criteria and a MADRS total score ≥30 at baseline. Patients were randomized to Trintellix 5 or 10 mg for 6 weeks or placebo. Mean baseline HAM-A total scores were 22.9 for placebo and 22.3 for Trintellix 10 mg.³

** Double-blind, parallel-group, placebo-controlled, active-reference study of 602 patients aged 18-65 years with a DSM-IV-TR diagnosis of MDD, a current MDE ≥3 months' duration, a MADRS total score ≥26, in addition to self-reported subjective cognitive dysfunction with a baseline score of <70 on the DSST. Patients were randomized to Trintellix 10 or 20 mg once daily (n=198) or placebo (n=194) for 8 weeks. Duloxetine 60 mg once daily (n=207) was included as the active reference arm to demonstrate assay sensitivity to traditional antidepressant outcomes. Mean baseline DSST scores were 43.5 for placebo, 42.3 for Trintellix 10-20 mg and 43.4 for duloxetine 60 mg.⁷

References: 1. Boulenger JP, et al. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. *Int Clin Psychopharmacol* 2014;29(3):138-49. 2. Data on file: Trintellix Coverage Canada. Lundbeck. December 2021. 3. Trintellix Product Monograph. Lundbeck Canada Inc., August 4, 2021. 4. Data on file. Lundbeck Canada Inc. February 2022. 5. Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. *Can J Psychiatry* 2016;61(9):540-60. 6. Alvarez E, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. *Int J Neuropsychopharmacol* 2012;15(5):589-600. 7. Mahableshwarkar AR, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. *Neuropsychopharmacology* 2015;40(8):2025-37.

Trintellix® is a registered trademark of H. Lundbeck A/S, used under license by Lundbeck Canada Inc.



VRT-B-100069-EV3

TRINTELLIX IMPROVED FUNCTION IN WORK, FAMILY AND SOCIAL LIFE IN PATIENTS WITH MDD (secondary endpoints)^{1*}



WORK LIFE
FAMILY LIFE
SOCIAL LIFE

COVERED
by most private insurance plans and public formularies across Canada (restrictions may apply)^{2†}

Demonstrated improvement in overall function (SDS score) from baseline at 8 weeks with Trintellix 20 mg vs placebo (secondary endpoint):

- Up to 87% improvement in **overall function** (-8.4 vs -4.5; $p=0.0005$)^{1*†}
- Up to 86% improvement in function at **work** (-2.6 vs -1.4; $p=0.0059$)^{1*†}
- Up to 82% improvement in function at **home** (-3.1 vs -1.7; $p<0.0001$)^{1*†}
- Up to 82% improvement in function in a **social setting** (-3.1 vs -1.7; $p<0.0001$)^{1*†}

† Trintellix® (vortioxetine) is indicated for the treatment of MDD in adults.³

‡ The starting and recommended dose of Trintellix is 10 mg once daily for adults <65 years of age. See the Product Monograph for complete dosing and administration information.

MDD=major depressive disorder; SDS=Sheehan Disability Scale

† Trintellix is eligible for reimbursement by Non-Insured Health Benefits, Veteran Affairs Canada and Correctional Service Canada, and for formulary coverage in the following provinces and territories: Quebec, Ontario, Alberta, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Northwest Territories, Yukon and British Columbia (special authorization). Refer to provincial formularies for more information.



Visit Trintellix.ca for more information



37.5 MILLION PATIENTS WORLDWIDE⁴

DEMONSTRATED TO TREAT MULTIPLE SYMPTOMS OF MDD^{1,3,6,7}

Depressive symptoms (MADRS total score)

Demonstrated
60%
improvement
(-18.8 vs -11.7)

from baseline at 8 weeks with Trintellix 20 mg vs 37% with placebo ($p < 0.0001$)^{1,3*†}

Anxiety symptoms (HAM-A score)

Demonstrated
51%
improvement
(-11.4 vs -8.41)

from baseline at 6 weeks with Trintellix 10 mg vs 37% with placebo ($p < 0.001$)^{6†}

Cognitive function symptoms (DSST score)

Demonstrated
61%
improvement
vs placebo
(4.6 vs 2.85)

from baseline at 8 weeks with Trintellix 10 to 20 mg ($p = 0.019$)^{7†**}

† The starting and recommended dose of Trintellix is 10 mg once daily for adults <65 years of age. See the Product Monograph for complete dosing and administration information.

CANMAT=Canadian Network for Mood and Anxiety Treatments; DSST=Digit Symbol Substitution Test; HAM-A=Hamilton Anxiety Rating Scale; MADRS=Montgomery-Åsberg Depression Rating Scale; MDD=major depressive disorder; SDS=Sheehan Disability Scale

§ See guidelines for complete recommendations.



TRINTELLIX HAS AN EXCELLENT TOLERABILITY PROFILE

The most commonly observed adverse events in patients with MDD treated with Trintellix in 6- to 8-week placebo-controlled studies (incidence $\geq 5\%$ and at least twice the rate of placebo) were nausea, constipation and vomiting.³



Low incidence of self-reported sexual side effects demonstrated

The incidence of self-reported sexual side effects was low and similar to placebo in clinical short- and long-term studies with Trintellix (5-20 mg/day).³

- Incidences for Trintellix and placebo, respectively, were: libido decreased (0.7%, 0.6%), orgasm abnormal (0.3%, 0.2%), anorgasmia (0.2%, 0%), loss of libido (0.2%, 0%), disturbance in sexual arousal (<0.1%, 0%), orgasm sensation decreased (<0.1%, <0.1%), sexual dysfunction (<0.1%, <0.1%).
- In males only: ejaculation delayed (0.5%, 0.1%), erectile dysfunction (0.3%, 0.4%), ejaculation disorder (<0.1%, 0%); in females only: vulvovaginal dryness (<0.1%, 0%).

Trintellix was associated with higher incidences of treatment-emergent sexual dysfunction compared with placebo, when evaluated by the Arizona Sexual Experience (ASEX) scale.³

- In females: Trintellix 5 mg/day 22% (N=65), 10 mg/day 23% (N=94), 20 mg/day 34% (N=67), placebo 20% (N=135).
- In males: Trintellix 5 mg/day 16% (N=67), 10 mg/day 20% (N=86), 20 mg/day 29% (N=59), placebo 14% (N=162).

Physicians should routinely inquire about possible sexual side effects during treatment with Trintellix.³



No clinically meaningful effect demonstrated on body weight

Mean weight change from baseline in a long-term (24-64 weeks), placebo-controlled study: +0.4 kg for Trintellix 5 or 10 mg/day, +0.1 kg for placebo.³



No clinically significant effect demonstrated on ECG parameters

Trintellix has not been associated with any clinically significant effect on ECG parameters, including QT, QTc, PR and QRS intervals, or with any arrhythmic potential.³

ECG=electrocardiogram



CONVENIENT ONCE-DAILY DOSING

Starting and recommended dose

 **10 mg** once daily
in adults <65 years of age.³

Dosage adjustment

 Increase to a maximum of  **20 mg** once daily as tolerated, depending on individual patient response.³

 Decrease to a minimum of  **5 mg** once daily may be considered for patients who do not tolerate higher doses.³

Patients ≥ 65 years of age

5 mg once-daily starting dose

Caution is advised when treating elderly patients with doses >10 mg/day due to limited efficacy and safety data from patients of 65 years of age or older who were treated with these doses in controlled clinical trials.³

May be taken with or without food³

† Trintellix is eligible for reimbursement by Non-Insured Health Benefits, Veteran Affairs Canada and Correctional Service Canada, and for formulary coverage in the following provinces and territories: Quebec, Ontario, Alberta, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Northwest Territories, Yukon and British Columbia (special authorization). Refer to provincial formularies for more information.



COVERED

by most private insurance plans and public formularies across Canada (restrictions may apply)^{2†}